David M. Morcos

David M. Morcos

Auto-generated profile, based on publicly available information

David M. Morcos

Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Closed access
LKLindsay K. Kozek
Lindsay K. Kozek
DMDavid Morcos
David Morcos
Sandra HoyekSandra Hoyek
Sandra Hoyek
NPNimesh A. Patel
Nimesh A. Patel
Purpose: To describe choriocapillaris loss on optical coherence tomography angiography (OCTA) imaging in a pediatric patient with congenital cytomegalovirus (CMV). Methods: A case was evaluated. Results: A 7-year-old female patient was referred for retinal evaluation of maculopathy in the right eye. She was diagnosed with congenital CMV at 14 months of age, at which time treatment was not deemed necessary. At 7 years of age, the patient was asymptomatic with 20/20 Snellen visual acuity. Funduscopy and colored fundus photographs showed macular scarring. Ancillary testing was performed, with retinal pigment epithelium alterations and disruption of the outer retinal layers seen on OCT and choriocapillaris loss in the area of the macular scar seen on OCTA. Conclusions: For patients with congenital CMV, OCTA imaging can show significant changes in choriocapillaris function. These changes do not necessarily correlate with visual function parameters. OCTA may be useful as an additional screening or surveillance modality for patients with congenital CMV or CMV retinitis.

19 May 2026 in Cornea
Verified
Journal Article
Closed access
DMDavid M. Morcos
David M. Morcos
BCBlaze A. Carbonell
Blaze A. Carbonell
NRNikhith Rao
Nikhith Rao
MKMelisa Karslioglu
Melisa Karslioglu
JFJosé A. P. M. Filho
José A. P. M. Filho
OLOlivia L. Lee
Olivia L. Lee
Purpose: To describe the risk factors, clinical course, and characteristics of 5 cases of acute calcific band keratopathy (BK) after the use of recombinant human nerve growth factor for neurotrophic keratitis. Methods: A single-center retrospective chart review of 43 eyes of 43 patients previously diagnosed with neurotrophic keratitis from April 2021 to October 2023 was conducted. All patients had previously completed at least one 8-week course of topical cenegermin 0.002%. Five of the 43 cenegermin-treated eyes that developed BK are included in this series. Results: The incidence of BK was 11.6%. The median time from treatment initiation to BK was 8 weeks. A corneal biopsy confirmed the presence of calcification in 2 cases. All 5 patients had persistent calcium deposits after discontinuing treatment. Prolonged epithelial defect healing time while on treatment was observed in patients who developed BK. Conclusions: BK was observed after cenegermin use. Herein, we report a series of 5 cases, which occurred at the same institution. Ethylenediaminetetraacetic acid chelation therapy had variable results, with 4 out of 5 patients requiring repeated surgical intervention because of multiple recurrences of BK.

2 December 2025 in Cornea
Verified
Journal Article
Closed access
DMDavid M. Morcos
David M. Morcos
TDThomas Dohlman
Thomas Dohlman
MDMarlene L. Durand
Marlene L. Durand
Purpose: To evaluate recent literature to determine the incidence and microbiology of endophthalmitis in eyes with the type 1 Boston Keratoprosthesis (BKPro). Methods: A literature review was performed using PubMed, Embase, and Cochrane databases. Studies were included if published ≥2010, included ≥20 BKPro eyes, and reported the mean follow-up time. Studies with duplicate data sets or limited to 1 type of underlying condition or age group were excluded. A meta-analysis was performed to calculate endophthalmitis incidence (cases per 100 eye-years). Results: Of 501 studies reviewed, 34 met inclusion criteria; these included 2732 BKPro eyes. The mean follow-up (range 1.4–8.9 years) was <5 years in 85% of studies. A total of 161 eyes developed endophthalmitis. Most studies reported the proportion of their cohort that developed endophthalmitis (0%–22%) but not the incidence. The pooled mean incidence of endophthalmitis was 2.09 cases per 100 eye-years (95% CI, 1.63–2.67). In 44 endophthalmitis cases with complete microbiology, 54.5% were bacterial (two thirds because of gram-positive bacteria), 29.5% fungal (primarily Candida ), and 16% no growth. Some cases occurred despite topical antibiotics effective against the endophthalmitis pathogen. Risk factors included antecedent keratitis, noncompliance with prophylactic antibiotics, corneal melt around the BKPro, and an exposed glaucoma drainage device. Conclusions: The incidence of endophthalmitis in BKPro eyes is 2 cases per 100-eye years, based on 34 recent studies with relatively short follow-up times. Future studies should report endophthalmitis incidence rather than proportion. More studies with long follow-up times will be helpful in determining the 5- and 10-year risk of endophthalmitis.